Filing Flows › Insulet (PODD) › Q3 2026 › vs Q3 2025
Insulet (PODD) Q3 2026 vs Q3 2025 (year over year)
Insulet's revenue rose $136M (+19%) from $706M in Q3 2025 to $842M in Q3 2026. The biggest changes: Total Omnipod products +$137M (+20%); Drug Delivery −$1.6M (-23%). Gross margin 75.1% against 72.2% (+2.8 pts).
Insulet, Q3 2026: revenue $842M (+19% year over year), operating margin 22.5%, net earnings $141M, operating cash flow $124M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 75.1% | 72.2% | +2.8 pts |
| Operating margin | 22.5% | 16.7% | +5.9 pts |
| Net margin | 16.8% | 12.4% | +4.4 pts |
| Free cash flow margin | 7.9% | 14.2% | -6.3 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| U.S. | $570M | $497M | $73.3M | +15% |
| International | $266M | $202M | $64.1M | +32% |
| Total Omnipod products | $837M | $699M | $137M | +20% |
| Drug Delivery | $5.5M | $7.1M | −$1.6M | -23% |
| Revenue | $842M | $706M | $136M | +19% |
| Gross profit | $632M | $510M | $122M | +24% |
| Cost of revenue | $210M | $196M | $13.7M | +7% |
| Operating profit | $190M | $118M | $72.1M | +61% |
| Operating expenses | $442M | $392M | $49.9M | +13% |
| Pre-tax earnings | $177M | $123M | $54.4M | +44% |
| Other expense, net | $12.6M | −$5.1M | $17.7M | — |
| Research & development | $91.6M | $77.2M | $14.4M | +19% |
| SG&A | $351M | $315M | $35.5M | +11% |
| Net earnings | $141M | $87.6M | $53.5M | +61% |
| Income tax | $36.1M | $35.2M | $900K | +3% |
| Depreciation & amortization | $28.2M | $22.0M | $6.2M | +28% |
| Share-based compensation | $20.6M | $16.7M | $3.9M | +23% |
| Working capital & other | $66.4M | $600K | $65.8M | 111× |
| Operating cash flow | $124M | $126M | −$2.2M | -2% |
| Free cash flow (OCF − capex) | $66.4M | $100M | −$33.7M | -34% |
| Capital expenditures | $57.1M | $25.6M | $31.5M | +123% |
Questions
How much did Insulet's revenue grow year over year in Q3 2026?
Insulet's revenue rose $136M (+19%) from $706M in Q3 2025 to $842M in Q3 2026.
What drove Insulet's revenue change in Q3 2026?
Total Omnipod products +$137M (+20%); Drug Delivery −$1.6M (-23%).